Affibody to start clinical development of a approach for the diagnosis of cancer

Swedish MPA gives go ahead for the clinical trial of Affibody's molecular imaging agent designed to improve the diagnosis of HER2-positive breast cancer.

28-Sep-2007

Affibody Holding AB has received a letter from the Swedish Medical Product Agency (MPA) allowing it to begin an exploratory clinical trial of a new approach for diagnosing an aggressive form of breast cancer. The approach, which is based on the Company's lead proprietary targeting Affibody® molecule, is designed to allow clinicians both to identify and locate breast cancer tumors over-expressing the cell membrane protein HER2. In the USA and Europe it is estimated that more than 550 000 women are diagnosed with breast cancer every year, of which approximately 25% of these, predominantly younger women, have the aggressive HER2-positive form.

The approach developed by Affibody is based on molecular imaging and is expected to offer clinicians a quick and efficient method for diagnosing HER2 positive breast cancer without the need for biopsies. Using nuclide-labeled Affibody® molecules that selectively bind only to HER2 on cancer tumors, and a scanning camera that can detect radioactivity, both the primary tumor and any metastases expressing the HER2 protein within the body can be visualized on a computer screen. The image, which is produced in less than 4 hours, will enable the clinician to rapidly identify, localize and assess the spread of the HER2-positive disease, if present. Affibody's approach, therefore delivers important disease-relevant information designed to help select the treatment most suitable for individual cancer patients.

https://www.bionity.com/en/news/70791/affibody-to-start-clinical-development-of-a-approach-for-the-diagnosis-of-cancer.html